Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Multiple Myeloma 1Head and Neck Neoplasms 1

Interventions

Cisplatin 30Radiotherapy 24pembrolizumab 21Cetuximab 21Docetaxel 13Fluorouracil 12Radiotherapy, Intensity-Modulated 10Paclitaxel 9Radiation 8Nivolumab 7Everolimus 7Carboplatin 7Oxaliplatin 6Gemcitabine 5Surgical Procedures, Operative 4Radiosurgery 4Magnetic Resonance Spectroscopy 4Gefitinib 4Erlotinib Hydrochloride 4Amifostine 4Pemetrexed 3Filgrastim 3Capecitabine 3Bleomycin 3Biopsy 3zalutumumab 2spartalizumab 2pegfilgrastim 2niraparib 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Head and Neck Neoplasms × perifosine × Clear all
NCT00062387 2013-06-03

Perifosine in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
46 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡